190 related articles for article (PubMed ID: 31467126)
21. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia.
Paganin M; Ferrando A
Blood Rev; 2011 Mar; 25(2):83-90. PubMed ID: 20965628
[TBL] [Abstract][Full Text] [Related]
22. Convergence of the ZMIZ1 and NOTCH1 pathways at C-MYC in acute T lymphoblastic leukemias.
Rakowski LA; Garagiola DD; Li CM; Decker M; Caruso S; Jones M; Kuick R; Cierpicki T; Maillard I; Chiang MY
Cancer Res; 2013 Jan; 73(2):930-41. PubMed ID: 23161489
[TBL] [Abstract][Full Text] [Related]
23. The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
Mendes RD; Canté-Barrett K; Pieters R; Meijerink JP
Haematologica; 2016 Sep; 101(9):1010-7. PubMed ID: 27582570
[TBL] [Abstract][Full Text] [Related]
24. DDX5 is a positive regulator of oncogenic NOTCH1 signaling in T cell acute lymphoblastic leukemia.
Lin S; Tian L; Shen H; Gu Y; Li JL; Chen Z; Sun X; You MJ; Wu L
Oncogene; 2013 Oct; 32(40):4845-53. PubMed ID: 23108395
[TBL] [Abstract][Full Text] [Related]
25. The NOTCH1/CD44 axis drives pathogenesis in a T cell acute lymphoblastic leukemia model.
García-Peydró M; Fuentes P; Mosquera M; García-León MJ; Alcain J; Rodríguez A; García de Miguel P; Menéndez P; Weijer K; Spits H; Scadden DT; Cuesta-Mateos C; Muñoz-Calleja C; Sánchez-Madrid F; Toribio ML
J Clin Invest; 2018 Jul; 128(7):2802-2818. PubMed ID: 29781813
[TBL] [Abstract][Full Text] [Related]
26. Synergistic antileukemic therapies in
Sanchez-Martin M; Ambesi-Impiombato A; Qin Y; Herranz D; Bansal M; Girardi T; Paietta E; Tallman MS; Rowe JM; De Keersmaecker K; Califano A; Ferrando AA
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):2006-2011. PubMed ID: 28174276
[TBL] [Abstract][Full Text] [Related]
27. Notch Partners in the Long Journey of T-ALL Pathogenesis.
Toribio ML; González-García S
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674902
[TBL] [Abstract][Full Text] [Related]
28. NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951.
Clappier E; Collette S; Grardel N; Girard S; Suarez L; Brunie G; Kaltenbach S; Yakouben K; Mazingue F; Robert A; Boutard P; Plantaz D; Rohrlich P; van Vlierberghe P; Preudhomme C; Otten J; Speleman F; Dastugue N; Suciu S; Benoit Y; Bertrand Y; Cavé H;
Leukemia; 2010 Dec; 24(12):2023-31. PubMed ID: 20861920
[TBL] [Abstract][Full Text] [Related]
29. The common oncogenomic program of NOTCH1 and NOTCH3 signaling in T-cell acute lymphoblastic leukemia.
Choi SH; Severson E; Pear WS; Liu XS; Aster JC; Blacklow SC
PLoS One; 2017; 12(10):e0185762. PubMed ID: 29023469
[TBL] [Abstract][Full Text] [Related]
30. IL-7R is essential for leukemia-initiating cell activity of T-cell acute lymphoblastic leukemia.
González-García S; Mosquera M; Fuentes P; Palumbo T; Escudero A; Pérez-Martínez A; Ramírez M; Corcoran AE; Toribio ML
Blood; 2019 Dec; 134(24):2171-2182. PubMed ID: 31530562
[TBL] [Abstract][Full Text] [Related]
31. NOTCH1 pathway activating mutations and clonal evolution in pediatric T-cell acute lymphoblastic leukemia.
Kimura S; Seki M; Yoshida K; Shiraishi Y; Akiyama M; Koh K; Imamura T; Manabe A; Hayashi Y; Kobayashi M; Oka A; Miyano S; Ogawa S; Takita J
Cancer Sci; 2019 Feb; 110(2):784-794. PubMed ID: 30387229
[TBL] [Abstract][Full Text] [Related]
32. Downregulation of Glutamine Synthetase, not glutaminolysis, is responsible for glutamine addiction in Notch1-driven acute lymphoblastic leukemia.
Nguyen TL; Nokin MJ; Terés S; Tomé M; Bodineau C; Galmar O; Pasquet JM; Rousseau B; van Liempd S; Falcon-Perez JM; Richard E; Muzotte E; Rezvani HR; Priault M; Bouchecareilh M; Redonnet-Vernhet I; Calvo J; Uzan B; Pflumio F; Fuentes P; Toribio ML; Khatib AM; Soubeyran P; Murdoch PDS; Durán RV
Mol Oncol; 2021 May; 15(5):1412-1431. PubMed ID: 33314742
[TBL] [Abstract][Full Text] [Related]
33. Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia.
Xi M; Guo S; Bayin C; Peng L; Chuffart F; Bourova-Flin E; Rousseaux S; Khochbin S; Mi JQ; Wang J
Front Med; 2022 Jun; 16(3):442-458. PubMed ID: 34669156
[TBL] [Abstract][Full Text] [Related]
34. T cell acute lymphoblastic leukemia/lymphoma: a human cancer commonly associated with aberrant NOTCH1 signaling.
Pear WS; Aster JC
Curr Opin Hematol; 2004 Nov; 11(6):426-33. PubMed ID: 15548998
[TBL] [Abstract][Full Text] [Related]
35. MAFB enhances oncogenic Notch signaling in T cell acute lymphoblastic leukemia.
Pajcini KV; Xu L; Shao L; Petrovic J; Palasiewicz K; Ohtani Y; Bailis W; Lee C; Wertheim GB; Mani R; Muthusamy N; Li Y; Meijerink JPP; Blacklow SC; Faryabi RB; Cherry S; Pear WS
Sci Signal; 2017 Nov; 10(505):. PubMed ID: 29138297
[TBL] [Abstract][Full Text] [Related]
36. Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and gamma-secretase inhibitors.
Silva A; Jotta PY; Silveira AB; Ribeiro D; Brandalise SR; Yunes JA; Barata JT
Haematologica; 2010 Apr; 95(4):674-8. PubMed ID: 20015880
[TBL] [Abstract][Full Text] [Related]
37. Dual antitumor mechanisms of Notch signaling inhibitor in a T-cell acute lymphoblastic leukemia xenograft model.
Masuda S; Kumano K; Suzuki T; Tomita T; Iwatsubo T; Natsugari H; Tojo A; Shibutani M; Mitsumori K; Hanazono Y; Ogawa S; Kurokawa M; Chiba S
Cancer Sci; 2009 Dec; 100(12):2444-50. PubMed ID: 19775286
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic antibody targeting of individual Notch receptors.
Wu Y; Cain-Hom C; Choy L; Hagenbeek TJ; de Leon GP; Chen Y; Finkle D; Venook R; Wu X; Ridgway J; Schahin-Reed D; Dow GJ; Shelton A; Stawicki S; Watts RJ; Zhang J; Choy R; Howard P; Kadyk L; Yan M; Zha J; Callahan CA; Hymowitz SG; Siebel CW
Nature; 2010 Apr; 464(7291):1052-7. PubMed ID: 20393564
[TBL] [Abstract][Full Text] [Related]
39. Leukemia-specific delivery of mutant NOTCH1 targeted therapy.
Roti G; Qi J; Kitara S; Sanchez-Martin M; Saur Conway A; Varca AC; Su A; Wu L; Kung AL; Ferrando AA; Bradner JE; Stegmaier K
J Exp Med; 2018 Jan; 215(1):197-216. PubMed ID: 29158376
[TBL] [Abstract][Full Text] [Related]
40. Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies.
Bernasconi-Elias P; Hu T; Jenkins D; Firestone B; Gans S; Kurth E; Capodieci P; Deplazes-Lauber J; Petropoulos K; Thiel P; Ponsel D; Hee Choi S; LeMotte P; London A; Goetcshkes M; Nolin E; Jones MD; Slocum K; Kluk MJ; Weinstock DM; Christodoulou A; Weinberg O; Jaehrling J; Ettenberg SA; Buckler A; Blacklow SC; Aster JC; Fryer CJ
Oncogene; 2016 Nov; 35(47):6077-6086. PubMed ID: 27157619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
